355 related articles for article (PubMed ID: 30636561)
1. Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
Crimi G; Morici N; Ferrario M; Ferri LA; Piatti L; Grosseto D; Cacucci M; Mandurino Mirizzi A; Toso A; Piscione F; De Carlo M; Elia LR; Trimarco B; Bolognese L; Bovenzi FM; De Luca G; Savonitto S; De Servi S
J Am Heart Assoc; 2019 Jan; 8(2):e010956. PubMed ID: 30636561
[TBL] [Abstract][Full Text] [Related]
2. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.
Savonitto S; Ferri LA; Piatti L; Grosseto D; Piovaccari G; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Rogacka R; Antonicelli R; Cesana BM; De Luca L; Ottani F; De Luca G; Piscione F; Moffa N; De Servi S;
Circulation; 2018 Jun; 137(23):2435-2445. PubMed ID: 29459361
[TBL] [Abstract][Full Text] [Related]
4. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
5. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
[TBL] [Abstract][Full Text] [Related]
6. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI.
Giustino G; Mehran R; Dangas GD; Kirtane AJ; Redfors B; Généreux P; Brener SJ; Prats J; Pocock SJ; Deliargyris EN; Stone GW
J Am Coll Cardiol; 2017 Oct; 70(15):1846-1857. PubMed ID: 28982497
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
[TBL] [Abstract][Full Text] [Related]
9. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
[TBL] [Abstract][Full Text] [Related]
10. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
11. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
[TBL] [Abstract][Full Text] [Related]
13. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Ferri LA; Morici N; Grosseto D; Tortorella G; Bossi I; Sganzerla P; Cacucci M; Sibilio G; Tondi S; Toso A; Ferrario M; Gandolfo N; Ravera A; Mariani M; Corrada E; Di Ascenzo L; Petronio AS; Cavallini C; Moffa N; De Servi S; Savonitto S
Am Heart J; 2016 Nov; 181():101-106. PubMed ID: 27823681
[TBL] [Abstract][Full Text] [Related]
14. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
[TBL] [Abstract][Full Text] [Related]
16. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
[TBL] [Abstract][Full Text] [Related]
17. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
[TBL] [Abstract][Full Text] [Related]
18. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
[TBL] [Abstract][Full Text] [Related]
19. Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome.
Fujii T; Endo S; Tsuchiya R; Nagamatsu H; Kasai S; Kawamura Y; Yoshimachi F; Ikari Y
Int J Cardiol; 2023 Mar; 375():1-6. PubMed ID: 36649890
[TBL] [Abstract][Full Text] [Related]
20. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
